What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

07/12/2016

PARIS, France – le 7 décembre 2016 – Lysogene, société biopharmaceutique spécialisée dans la thérapie génique ciblant les maladies rares du système nerveux central, annonce la nomination de David Schilansky au Conseil d’administration en tant que membre indépendant, non exécutif. Actuellement Directeur des Opérations et Directeur Général Délégué de DBV Technologies, société biopharmaceutique (Euronext : DBV ; NASDAQ : DBVT), M. Schilansky possède vingt années d’expérience managériale dans les domaines de la biotechnologie et de la finance.

« Nous sommes heureux d’accueillir David au sein de notre Conseil d’administration, où il veillera à la bonne mise en œuvre de la stratégie de développement de Lysogene » a déclaré Karen Aiach, CEO et fondatrice de Lysogene. « Ses solides compétences de direction et de gestion d’entreprise vont être cruciales alors que nous engageons le développement de nos programmes de thérapie génique dans la Mucopolysaccharidose de type A, la gangliosidose à GM1, ainsi que d’autres maladies potentiellement mortelles. »

En qualité de membre du comité exécutif de DBV Technologies, M. Schilansky supervise la mise en œuvre de la stratégie depuis janvier 2015, après avoir été Directeur Financier de la société en 2011. Auparavant, M. Schilansky a occupé différentes fonctions clés chez Ipsen Pharma, dont celle de Directeur Financier par intérim. Il a également travaillé chez Thomson Inc. (aujourd’hui Technicolor S.A.) en tant que co-responsable des relations investisseurs et chez Warburg Dillon Read (aujourd’hui UBS Investment Bank) dans le domaine des fusions et acquisitions.

« Lysogene est une société innovante, à croissance rapide, qui a déjà franchi des étapes importantes et dispose d’un solide potentiel de développement » commente M. Schilansky. « Je suis fier de rejoindre le Conseil d’administration de Lysogene durant cette phase de transformation pleine de promesses que connaît actuellement la société. »

À propos de la mucopolysaccharidose de type A (ou maladie de Sanfilippo A) et de la gangliosidose à GM1
La MPS IIIA est une maladie de surcharge lysosomale associée à des atteintes neurologiques sévères. Elle est due à une anomalie du gène SGSH transmise de manière autosomique et récessive et touche environ une pour 100.000 naissances. La MPS IIIA apparaît dans la petite enfance, provoquant une neurodégénerescence progressive associée à des troubles du comportement insolubles et à une régression du développement. Cette maladie est dévastatrice pour les patients et pour leur famille. Il n’existe aujourd’hui aucun traitement, et les patients meurent de façon précoce.
La gangliosidose à GM1 est une maladie rare neurodégénérative caractérisée par de graves retards de développement cognitif et moteur, entraînant la mort précoce des patients. La maladie est causée par une mutation du gène GLB1 qui code pour la bêta-galactosidase, une enzyme nécessaire au recyclage de la molécule GM1-gangliosidose dans les neurones. Ce lipide du cerveau est essentiel pour un fonctionnement normal, mais son accumulation entraine une neurodégénerescence et des symptômes neurologiques sévères. Il n’existe actuellement aucun traitement

À propos de Lysogene
Lysogene est une société de biotechnologie au stade clinique, pionnière dans la recherche fondamentale et le développement clinique de thérapies géniques utilisant des vecteurs dérivés de virus adéno-associés (AAV) dans des maladies du SNC pour lesquelles il existe d’importants besoins médicaux non satisfaits. Depuis 2009, Lysogene a mis en place une plate-forme et un réseau sans équivalent, avec des produits de pointe dans la MPS III A et dans la gangliosidose à GM1, pour s’affirmer comme un leader mondial dans les maladies orphelines du SNC.

Pour plus d’informations : www.lysogene.com.

Contact media France:
Annie-Florence Loyer
NewCap
afloyer@newcap.fr
+33 (0)1 44 71 00 12 + 33 (0)6 88 20 35 59
Contact media USA:

Marion Janic
RooneyPartners
mjanic@rooneyco.com
+1 (212) 223-4017

06/12/2016

Lausanne, Switzerland, December 6, 2016 – Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, today announced the appointment of J. Michael Ryan, M.D. as Chief Medical Officer. With over 15 years of Central Nervous System (CNS) clinical research experience, Michael brings extensive drug development expertise to Asceneuron. He will be responsible for advancing Asceneuron’s pipeline of innovative small molecules and progressing tau modifiers through the clinic.
Michael joins Asceneuron from Novartis Pharmaceuticals Corporation, where he was Vice President in the Neuroscience Development Franchise and Therapeutic Area Head for Neurodegeneration for five years. At Novartis, he worked on the clinical development strategy and led programmes in a number of CNS indications including Alzheimer’s disease, Parkinson’s disease and Schizophrenia. He has also held a number of senior clinical research and development positions at several multi-national companies including Pfizer, Wyeth Research, and MSD Research Laboratories (known as Merck Research Laboratories in the United States).
Michael completed training in geriatric psychiatry and neuropsychiatry at Dartmouth Medical School and has published over 30 scientific articles on neurodegenerative diseases. He has held academic positions at Dartmouth Medical School and the University of Rochester, where he co-directed the Geriatric Neurology & Psychiatry Clinic until 2004. Michael holds an M.D. in Medicine from the Medical University of South Carolina and a B.S. in Biology from Georgetown University.
Dirk Beher, CEO of Asceneuron, commented: “We are delighted to welcome Michael to the Asceneuron team. His outstanding track record and expertise in neurodegenerative disease are crucial as we are about to progress our first highly brain penetrant and orally bioavailable tau modifier into the clinic for the treatment of a number of orphan CNS disorders. We look forward to working with Michael in addressing this high unmet medical need and developing our pipeline to bring our innovative small-molecule therapeutics to patients.”
Michael Ryan, newly appointed CMO of Asceneuron, added: “Asceneuron is at an exciting stage of development as it looks to take its tau modifiers into the clinic. I look forward to working with such a highly experienced board and dynamic team as we progress the pipeline and develop important treatment options for patients with neurodegenerative diseases.”

For further information, please contact:
Asceneuron
Dirk Beher, CEO
Email: info@asceneuron.com
Hume Brophy
Conor Griffin, Alexia Faure, Alex Protsenko
Tel: +44 (0)20 7862 6395
Email: asceneuron@humebrophy.com

About Asceneuron
Asceneuron is an emerging biotech company excelling in the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical needs such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, is currently completing the critical regulatory studies to initiate human clinical testing. The O-GlcNAcase inhibitor is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron is a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. For more information, please visit www.asceneuron.com.

24/11/2016

Support from Financial and Strategic Investors Will Advance
Product Development and Commercialization Efforts

Fremont, Calif.— November 22, 2016 — Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced the closing of $45 million in Series C financing led by Sectoral Asset Management, with participation from mutual funds advised by T. Rowe Price Associates, Inc. and returning investors including Sofinnova Partners, Venrock, RA Capital, Deerfield, Ally Bridge Group and others.

Proceeds from the financing will be used to advance development of the company’s Lithoplasty® balloon catheter platform into new therapeutic areas and to expand commercialization of the technology for the treatment of peripheral vascular disease in both the United States and the European Union. The company’s near-term plans also include further study of Peripheral Lithoplasty devices in conjunction with drug coated balloons in a 300+ patient randomized controlled study called DISRUPT PAD III.

“When you consider the treatment challenges created by calcified lesions, it is clear there is a large market opportunity for Lithoplasty. The strong clinical results generated using a device built on a balloon-based platform offer a unique and compelling alternative to currently available therapies,” said Michael Sjöström, co-founder and Chief Investment Officer, Sectoral Asset Management and lead investor of this funding. “We look forward to supporting the management team as they take the company, and technology, to the next level.”

“We are very pleased to have Sectoral lead this financing with returning participation from our high quality investor base,” said Shockwave Medical CEO and co-founder Daniel Hawkins. “Lithoplasty is poised to be a paradigm-changing technology for the treatment of advanced cardiovascular disease. This financing will enable the company to continue taking the steps necessary to ensure the technology reaches its fullpotential.”

Shockwave Medical recently achieved of a series of important milestones including:
– FDA clearance of the company’s Lithoplasty System for lithotripsy-enhanced balloon dilation of lesions, including calcified lesions, in the peripheral vasculature, including the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries.
– Announcement of the upcoming DISRUPT PAD III study, the largest ever multicenter randomized study designed to exclusively enroll patients with calcified peripheral artery disease (PAD). The study will provide physicians foundational Level I evidence to guide therapy in this difficult-to-treat patient cohort.
– Presentation of positive results from the first study of Lithoplasty technology in the treatment of patients with calcified coronary artery disease.
“Shockwave is on a very successful trajectory to address the growing burden of calcium in cardiovascular disease using Lithoplasty,” said Antoine Papiernik, managing partner of Sofinnova Partners. “We are very pleased to add our continued support to that provided by a very strong investment syndicate. Collectively, this investor base offers the breadth of resources and depth of commitment needed to support the company’s vision of changing the treatment of advanced cardiovascular disease.”

About Shockwave Medical’s Lithoplasty® System
The Shockwave Medical Lithoplasty System is the first-ever device designed to selectively target hardened calcium in patients with cardiovascular disease. The system integrates the calcium-disrupting power of lithotripsy with the familiarity and simplicity of a balloon angioplasty. Built on a deliverable balloon catheter platform, the device emits intermittent sound waves (lithotripsy) that target and disrupt calcified plaques, which then require only a low-pressure balloon inflation to dilate the blockage and restore blood flow. The result is an effective and consistent revascularization of calcified lesions while minimizing complications.
The Peripheral Lithoplasty System is commercially available in the European Union and the United States for the treatment of peripheral vascular disease. To view an animation of the Lithoplasty System visit: http://shockwavemedical.com.

About Shockwave Medical
Shockwave Medical, based in Fremont, Calif., is working to reshape interventional therapy with Lithoplasty® Technology for the treatment of calcified peripheral vascular, coronary vascular and heart valve disease. For more information, visit www.shockwavemedical.com.

Media Contact:
Jessica Volchok
ir@shockwavemedical.com
310 849-7985

 

14/11/2016

LEIDEN, the Netherlands, Nov. 14, 2016 – ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis (CF) and Leber’s congenital amaurosis Type 10 (LCA10), today announced results for the third quarter of 2016.
“This quarter we completed our QR-010 nasal potential difference study and in October, we reported positive results from this study in homozygous ∆F508 patients. The outcomes were both statistically significant and clinically meaningful, marking an important step for about half of the global CF population.” said Daniel de Boer, Chief Executive Officer of ProQR “I’m proud of the team that has designed and executed this study in the most rigorous way leading to robust clinical proof of concept in the early phase of our development program. I also want to thank the patients that participated, and the clinical investigators that supported this unique and important trial”.

Financial Highlights
At September 30, 2016, ProQR held cash and cash equivalents of €64.9 million, compared to €76.3 million at June 30, 2016. Net cash used in operating activities during the three month period ended September 30, 2016 was €10.8 million, compared to €6.3 million for the same period last year.
Research and development costs increased to €8.3 million for the quarter ended September 30, 2016 from €6.0 million for the same period last year and comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities for our clinical studies, license and intellectual property costs and other allocated costs. The increase in expenses was primarily due to the advancement of our pipeline, which included clinical development of QR-010 for CF, preparations for the start of the first clinical trial of QR-110 for LCA10, and preclinical development activities of QR-313 for epidermolysis bullosa.
General and administrative costs increased to €2.0 million for the quarter ended September 30, 2016 from €1.5 million for the same period last year, primarily due to increased investments in our facilities and our support organization.
Net result for the three month period ended September 30, 2016 was a €10.1 million loss or €0.43 per share, compared to a €6.3 million loss or €0.27 per share for the same period last year. For further financial information for the period ending September 30, 2016, please refer to the financial statements appearing at the end of this release.

Corporate Highlights
• In July 2016, QR-010 received a Fast Track designation by the US Food and Drug Administration (FDA). Drugs that are under development for serious conditions and have the potential to fulfill an unmet medical need can receive this designation. It was established with the intention to bring promising drugs to patients sooner by facilitating the development with more frequent FDA interactions and expediting the review process.
• During the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) September 25 – 28, 2016 the company presented a poster titled: ‘QR-010 Restores CFTR Function in Models of ∆F508 mediated Cystic Fibrosis’. The poster summarized some of the exciting pre-clinical work published earlier and new data showing that repeated nebulization of QR-010 did not change the diffusion speed of QR-010 in in vitro models of CF-like mucus. The poster also featured new data showing that QR-010 was stable in the presence of clinically relevant levels of several CF standard-of-care therapies.
• During OTS, the company also presented a poster titled ‘QR-110 Treatment for Leber’s Congenital Amaurosis Type 10 due to the p.Cys998X Mutation in CEP290’. This data shows that QR-110 can restore CEP290 mRNA and protein levels in primary LCA10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, and other extensive preclinical work, the company plans to start a first-in-human study in adult and pediatric subjects in the first half of 2017.
• This quarter, the company advanced QR-313 (previously named QRX-313) into pre-clinical development for the treatment of dystrophic epidermolysis bullosa (DEB). QR-313 is an RNA oligonucleotide designed to induce the exclusion of a part of the COL7A1 RNA (exon skipping) that contains a disease causing mutation with the aim to restore functional collagen type VII (C7) protein and with that the anchoring fibrils that bind the layers of skin together. The clinical program for QR-313 is expected to start in 2018.

Subsequent events
• During the North American Cystic Fibrosis conference (NACFC) October 26 – 29, 2016 the company presented positive results from PQ-010-002, a proof-of-concept study demonstrating that QR-010 restores CFTR function in patients homozygous for ∆F508. CFTR is the protein channel that is defective in patients with CF, and presence or absence of function of CFTR can be measured with the nasal potential difference (NPD) assay. Following 4 weeks of topical therapy, QR-010 improved the CFTR-mediated total chloride response, a direct measure of CFTR function. QR-010 also restored other indicators of CFTR function. In subjects that were compound heterozygous for the ∆F508 mutation, no meaningful difference was measured. QR-010 was observed to be safe and well-tolerated in all subjects.
• During NACFC the company also announced that clinical study PQ-010-001 completed all four single-dose cohorts and blinded safety data from all cohorts was shared. PQ-010-001 is a placebo-controlled Phase 1b study in subjects with CF homozygous for ∆F508. QR-010 was observed to be safe and well-tolerated in all cohorts. The multiple dose cohorts in this study are ongoing and topline safety, tolerability and exploratory efficacy data from this study are expected in mid-2017.

About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe orphan diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

About QR-010
QR-010 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of the disease by targeting the mRNA in CF patients that have the ∆F508 mutation. The ∆F508 mutation is a deletion of three of the coding base pairs, or nucleotides, in the CFTR gene, which results in the production of a misfolded CFTR protein that does not function normally. QR-010 is designed to bind to the defective CFTR mRNA and to restore CFTR function. QR-010 is designed to be self-administered via an optimized eFlow® Nebulizer (PARI Pharma GmbH). eFlow® is a small, handheld aerosol delivery device which nebulizes QR-010 into a mist inhaled directly into the lungs. QR-010 has been granted orphan drug designation in the United States and the European Union and fast-track status by the FDA. The QR-010 project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 633545.

About QR-110
QR-110 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of Leber’s congenital amaurosis Type 10 due to the p.Cys998X mutation in the CEP290 gene. The p.Cys998X mutation is a substitution of one nucleotide in the pre-mRNA that leads to aberrant splicing of the mRNA and non-functional CEP290 protein. QR-110 is designed to restore wild-type CEP290 mRNA leading to the production of wild-type CEP290 protein by binding to the mutated location in the pre-mRNA causing normal splicing of the pre-mRNA. QR-110 is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union.

About QR-313
QR-313 is a first-in-class RNA-based oligonucleotide designed to address the underlying cause of dystrophic epidermolysis bullosa (DEB) due to mutations in exon 73 of the COL7A1 gene. Mutations in this exon can cause loss of functional collagen type VII (C7) protein. Absence of C7 results in the loss of anchoring fibrils that normally link the dermal and epidermal layers of the skin together. QR-313 is designed to exclude exon 73 from the mRNA (exon skipping) and produce truncated but functional C7 protein and thereby restores functionality of the anchoring fibrils.

FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-010, QR-110 and QR-313, and the clinical development and the therapeutic potential thereof, statements regarding our ongoing and planned discovery and development of product candidates and the timing thereof, including those in our innovation pipeline, statements regarding release of clinical data, and statements regarding the Horizon 2020 program. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, including that positive results observed in our prior and ongoing studies may not be replicated in later trials or guarantee approval of any product candidate by regulatory authorities, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com

08/11/2016

Funding brings resources to conduct first-in-man study designed to transform LVAD therapy

PARIS, November 4th, 2016 – CorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing shareholders including Sofinnova Partners, Bpifrance and Seventure were joined by two new investors: Novo Seeds, which led the round, and Ysios Capital. Emmanuelle Coutanceau from Novo Seeds and Josep Lluis Sanfeliu from Ysios will join the CorWave board of directors as well as cardiovascular industry veteran Michel Darnaud, who will serve as an independent director.

CorWave was incorporated by MD Start, a European medtech incubator, in 2011 and raised a Series A in 2013. Gérard Hascoët, who led the incubation phase and now serves as chairman of CorWave, said: “Since day one we saw an unparalleled match between this unique technology invented in France and the unmet needs in the heart failure space. Medtech expertise, engineering and funding was required to bridge the gap.”

Heart failure is one of the leading causes of death globally. Heart transplant is the most effective treatment for end-stage heart failure but is reserved for a minority of patients. LVADs are mechanical pumps implanted below the native heart that can restore blood flow to normal levels and correct the main symptoms associated with heart failure. LVADs can give 10 years of additional life to patients but current technologies create a non-physiological flow and are associated with a high risk of serious adverse events. After two years of support, over 80% of patients will be affected by at least one debilitating complication caused by the pump itself, mainly stroke, bleeding and infection. CorWave has developed a disruptive pumping technology that mimics the native heart flow pattern and could overcome these limitations of rotary pump LVADs.

Louis de Lillers, CEO of CorWave, said: “Our R&D team led by Carl Botterbusch, an LVAD veteran, has done a fantastic job at de-risking CorWave’s technology. Clinicians and scientists in the field as well as our engineers are gathering increasing evidence indicating that our technology has the potential to improve dramatically the clinical outcomes of LVADs. With this funding in place, we now have the resources to prepare our pump for the first-in-man study and bring this paradigm-shifting technology into the hands of clinicians.”

Antoine Papiernik of Sofinnova Partners added: “We are excited to continue backing CorWave’s talented management team and are convinced that CorWave could be the next big thing in LVAD and, more broadly, chronic heart failure treatment.”

This fundraising has been closed despite increasing expectations from cardiac surgeons but only incremental innovations on massive investments from large medtech companies that have failed to improve significantly the clinical outcome of LVADs.

Emmanuelle Coutanceau from Novo Seeds said: “Our due diligences showed that CorWave is perfectly aligned with the expectations of cardiac surgeons and cardiologists alike. We are pleased to join CorWave in its effort to turn this vision into reality.”

Josep Lluis Sanfeliu of Ysios added: “The LVAD market has attracted medtech giants in past 18 months with the acquisition of Thoratec by St-Jude for $3.4 billion and HeartWare by Medtronic for $1.1 billion. It is to be one of the hottest sectors in medtech. With the potential to topple rotary pumps’ hegemony, CorWave has everything to become the next European medtech success story.”

About CorWave SA
CorWave develops innovative cardiac assist devices. The wave membrane technology is a unique and disruptive technology protected by seven patent families. It is stemming from over 10 years of research led by academic laboratories and AMS R&D. Mimicking cardiac pulsation and limiting blood damage, CorWave LVAD should reduce serious adverse events associated with currently available devices and therefore improve the quality of care of end stage heart failure patients, a market with multi-billion dollar potential. The company was founded in 2011 by Paris-based incubator MD Start and won the World Innovation Challenge in 2016. CorWave is funded by leading investors including Bpifrance, Novo, Medtronic, Seventure, Sofinnova Partners and Ysios. The company employs a team of 20 engineers and researchers in downtown Paris at the Pepiniere Paris Sante Cochin. More information on: www.corwave.com

About Novo A/S
Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation. The company is the holding company in the Novo Group and responsible for managing the Foundation’s assets. Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. More information on: www.novo.dk

About Ysios Capital
Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical devices. Founded in 2008, Ysios Capital currently has over €200M ($220M) in assets under management, distributed over two funds. More information on: www.ysioscapital.com

About Bpifrance
Bpifrance, a subsidiary of the French state and the Caisse des Dépôts and the entrepreneurs’ trusted partner, finances businesses from the seed phase to IPO, through loans, guarantees and equity investments. Bpifrance also provides operational services and strong support for innovation, export, and external growth in partnership with Business France and Coface. Bpifrance offers businesses a large range of financing opportunities at each key step of their development, including offers adapted to regional specificities. With its 42 regional offices (90% of decisions are made locally) Bpifrance represents a strategic tool for economic competitiveness dedicated to entrepreneurs. Bpifrance acts as a back-up for initiatives driven by the French State and the Regions to tackle 3 goals: contribute to SME’s growth; prepare tomorrow’s competitiveness; contribute to the development of a positive entrepreneur ecosystem. With Bpifrance, businesses benefit from a powerful, efficient and close representative, to answer all their needs in terms of financing, innovation and investment. More information on: www.bpifrance.fr

About Seventure Partners
With over €600M in assets under management as of the end of 2015, Seventure Partners is a leading venture capital firm in Europe. Since 1997, Seventure Partners has invested in innovative businesses with high growth potential in digital technologies, in France and Germany, and in the Life Sciences field across Europe and North America. In Life Sciences, the main areas of focus include biotechnology and pharmaceuticals, connected health and medtech, industrial biotechnology, microbiome, nutrition, foodtech and personalized medicine. More information on: www.seventure.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.5 billion under management. More information on: www.sofinnova.fr.

US Media Contact:
Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108, rtrahan@ronaldtrahan.com

Europe Media Contact: ComCorp
Adélaïde Manester, +33 1 58 18 32 44, +33 6 70 45 74 37, amanester@comcorp.fr
Anne Hardy, +33 1 58 18 32 51, +33 6 13 56 23 96, ahardy@comcorp.fr

CorWave SA Contact : Louis de Lillers, CEO, +33 1 80 49 19 30, contact@corwave.com

02/11/2016
12/10/2016

Bio-based furandicarboxylic acid (FDCA) as main building block for the new polymer polyethylenefuranoate (PEF)

  • FDCA production plant with up to 50,000 tons capacity planned
  • PEF with multiple application opportunities like packaging, engineering plastics, coatings, and fibers
  • Starting point to build up world-leading positions in FDCA and PEF

Ludwigshafen, Germany, and Amsterdam, Netherlands – October 7, 2016 – BASF und Avantium, the renewable chemistry company, today announced the formation of a joint venture (JV) for the production and marketing of furandicarboxylic acid (FDCA), which is produced from renewable resources, as well as the marketing of the new polymer polyethylenefuranoate (PEF) based on the new chemical building block FDCA.

The aim of the JV named Synvina with headquarters in Amsterdam, The Netherlands, is to build up world-leading positions in FDCA and PEF. It is planned to invest a mid-three-digit million euro sum to build a reference plant with an annual capacity of up to 50,000 metric tons per year at BASF’s Verbund site in Antwerp, Belgium, and to license the technology for industrial scale production. For the production of FDCA, Synvina will use the YXY process® developed by Avantium which is based on fructose as renewable raw material.

FDCA-based PEF: multiple application opportunities and better performance

Industry experts consider bio-based FDCA to be a promising platform chemical and a building block for various downstream products for different applications. Most significantly, FDCA is used for the production of PEF, a polyester suitable for food and beverage packaging as well as for fibers for carpets and textiles. For the packaging industry, PEF offers better characteristics in comparison to conventional plastics, such as improved barrier properties for gases like carbon dioxide and oxygen, leading to a longer shelf life of packaged products. It also offers a higher mechanical strength, thus thinner PEF packaging can be produced and fewer resources are required. PEF is suitable for foil pouches, bottles for carbonated and non-carbonated soft drinks, water, dairy products, still and sports drinks and alcoholic beverages as well as personal and home care products. Alongside the polyester PEF, FDCA can be processed to polyamides for engineering plastics and fibers, to polyurethanes for foams, coatings and adhesives and to esters for personal care products and lubricants.

Synvina to continue Avantium’s partnering activities with leading companies

Synvina will continue Avantium’s established partnering activities with leading brands associated with FDCA and PEF. The goal of the cooperation platform is to develop a complete supply chain for PEF as sustainable bio-based packaging material. Together with Toyobo, the companies will jointly boost the PEF polymerization and further develop PEF films for food packaging, in electronics applications such as displays or solar panels, industrial and medical packages. With Mitsui, Synvina will work on developing PEF thin films and PEF bottles in Japan. Furthermore, Synvina aims to continue the development partnerships with The Coca Cola Company, Danone, ALPLA and other companies on the Joint Development Platform for PEF bottles.

BASF and Avantium providing prerequisites for excellent starting position

“With Synvina we will enter the promising business with FDCA and PEF and support our customers in the various industries to create value. We strongly believe that the future belongs to these products because they combine superior characteristics with a production process based on renewable feedstock,” said Dr. Stefan Blank, President of BASF’s Intermediates division. “Synvina is an innovative and highly competent company with an excellent starting position from which to build a globally leading role in FDCA and PEF.”

“FDCA is a sleeping giant with huge potential. Although it was first produced in the 1950s, it has never been successfully developed and brought to market until now,” said Tom van Aken, Chief Executive Officer of Avantium. “I strongly believe that Synvina will wake up that sleeping giant and make it available for industrial use. With the development of a proven FDCA production process and the construction of a strong partnering and cooperation network, Avantium has provided Synvina with all necessary prerequisites. It will benefit from BASF’s expertise in market development and large-scale production and as a reliable chemical company in the business of intermediates and polymers.”

About Avantium
Avantium is a leading chemical technology company and a forerunner in renewable chemistry. Together with its partners around the world, Avantium develops efficient processes and sustainable products made from biobased materials. Avantium offers a breeding ground for revolutionary renewable chemistry solutions. From invention to commercially viable production processes. One of Avantium’s many success stories is YXY technology®, with which they created PEF: a completely new, high-quality plastic made from plant-based industrial sugars. PEF is 100% recyclable. It therefore offers a cost-effective solution to make anything from a wide range of plastic bottles and packaging to fibers. YXY is the most advanced technology, but Avantium is also working on a host of other ground-breaking projects and is providing advanced catalysis research services and systems to the leading chemical and petrochemical companies. Avantium’s offices and headquarters are based in Amsterdam, the Netherlands. Further information at www.avantium.com

About BASF Intermediates
The BASF Group’s Intermediates division develops, produces and markets a comprehensive portfolio of about 700 intermediates around the world. Its most important product groups include amines, diols, polyalcohols, acids and specialties. Intermediates are used for example as starting materials for coatings, plastics, pharmaceuticals, textiles, detergents and crop protectants. Innovative intermediates from BASF help to improve both the properties of final products and the efficiency of production processes. The ISO 9001 certified Intermediates division operates plants at production sites in Europe, Asia and North America. Around the globe, the division generated sales to third parties of about €2.8 billion in 2015. Further information at www.intermediates.basf.com

About BASF
At BASF, we create chemistry for a sustainable future. We combine economic success with environmental protection and social responsibility. The approximately 112,000 employees in the BASF Group work on contributing to the success of our customers in nearly all sectors and almost every country in the world. Our portfolio is organized into five segments: Chemicals, Performance Products, Functional Materials & Solutions, Agricultural Solutions and Oil & Gas. BASF generated sales of more than €70 billion in 2015. BASF shares are traded on the stock exchanges in Frankfurt (BAS), London (BFA) and Zurich (AN). Further information at www.basf.com.
Media contacts:

BASF SE
Klaus-Peter Rieser
Intermediates Division
Phone: +49 621 60 95138
E-mail: klaus-peter.rieser@basf.com

Avantium
Alex de Vries
Phone: +31 20 586 0132
Mobile: + 31 651 11 9205
E-mail: alex.de.vries@msl.nl

11/10/2016

– Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics-
-Takeda makes investment in Crescendo-

Cambridge, UK, Cambridge, Mass. and Osaka, Japan – 10 October 2016 – Crescendo Biologics Limited (Crescendo), the drug discovery and developer of Humabody®-based therapeutics, and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced a global, strategic, multi-target collaboration and license agreement for the discovery, development and commercialization of Humabody® -based therapeutics for cancer indications with a high unmet medical need.

Crescendo will use its proprietary transgenic platform and engineering expertise to discover and optimally configure Humabody® candidates (Humabody® Drug Conjugates and Immuno-Oncology modulators) against multiple targets selected by Takeda.

“We see significant potential in Crescendo and its innovative technology to develop unique, small and customizable Humabody®-based therapeutics,” said Andrew Plump M.D., Ph.D., Chief Medical and Scientific Officer, Takeda. “Collaborations are critical to helping us achieve our aspiration of curing cancer. Working together with Crescendo will enable us to leverage its important technology to support Takeda’s goal of developing next generation, highly modular and targeted therapies to treat cancer.”
“This collaboration with Takeda represents a significant step forward for Crescendo. It provides validation of our transgenic platform and our capabilities to rapidly assemble and configure small, differentiated Humabody®-based therapeutics, opening routes to novel biology,” said Dr. Peter Pack, CEO, Crescendo Biologics. “As a leading global pharmaceutical company, Takeda brings extraordinary expertise in the oncology area with significant capabilities in developing and delivering novel medicines to patients. This first major collaboration enables us to potentially broaden and accelerate innovative Humabody®-based product candidates. ”
Under the terms of the agreement, Crescendo is eligible to receive up to $36 million, in a combination of an upfront payment, investment, research funding and preclinical milestones. Takeda will have the right to develop and commercialize Humabody®-based therapeutics resulting from the collaboration. Crescendo is also eligible to receive further clinical development, regulatory and sales-based milestone payments of up to $754 million. In addition, Crescendo will be eligible to receive royalties on Humabody®-based product sales by Takeda.
Takeda signed agreements with Crescendo Biologics through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.

For more information, please contact:
Crescendo Biologics
Dr Peter Pack, CEO Tel:44 (0)1223 497140
info@crescendobiologics.com

Instinctif Partners
Dr Christelle Kerouedan / Melanie Toyne-Sewell Tel:44 (0)20 7457 2020
crescendo@instinctif.com

Takeda
Japanese Media
Tsuyoshi Tada
Tel: +81 (0) 3-3278-2417
tsuyoshi.tada@takeda.com
Takeda
Media outside Japan
Sara Noonan Tel: +1 617-551-3683
sara.noonan@takeda.com
About Crescendo Biologics Ltd
Crescendo Biologics is a biopharmaceutical company involved in discovering and developing potent, highly differentiated Humabody® therapeutics with a focus on cancer. The Company’s Humabody® therapeutics are based on its proprietary, robust and highly efficient fully human VH domain technology platform.
Crescendo is building a pipeline of new differentiated medicines, including Humabody® Drug Conjugates (HDCs) and multi-specific immuno-oncology (IO) modulators, through in-house development and strategic partnerships.
Crescendo’s technology platform is centred on a unique and proprietary transgenic mouse, which enables the benefits of in vivo maturation to be harnessed thereby naturally optimising the affinity and biophysical properties of Humabodies. Compared with monoclonal antibodies, Humabodies offer a unique combination of potential benefits that results from their small size, cost-effective production and modular plug & play engineering options for generating novel bi- or multi-specific formats.
Crescendo is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Imperial Innovations, Astellas Venture Management and EMBL Ventures.
For more information, please visit the website: www.crescendobiologics.com

About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com/news.

Additional information about Takeda is available through its corporate website, www.takeda.com, and additional information about Takeda Oncology, the brand for the global oncology business unit of Takeda Pharmaceutical Company Limited, is available through its website, www.takedaoncology.com.

About Humabodies®
Humabodies® are a novel class of extremely small in size, robust and potent protein therapeutics. They are based on fully human VH domain building blocks. Humabodies® have excellent biophysical properties enabling the extremely rapid and efficient assembly and screening of a variety of bi- and multi-specific Humabody® candidates, opening new routes to novel biology and modes-of-action.
Using its proprietary transgenic Humabody® platform, Crescendo is developing a growing pipeline of next generation cancer therapeutics based on Humabody® Drug Conjugates (HDCs) and multi-specific Immuno-Oncology (IO) modulators.
Crescendo is working to validate the Humabody® format through strategic collaborations and establish clinical proof of concept for Humabody® therapeutics, either in-house or with key partners.
HDCs are created utilising homogeneous, site-specific conjugation of linkers and toxic payloads. They have enhanced specificity and superior toxicology profiles to standard ADCs resulting in a superior Therapeutic Index over standard ADCs (enabled by a “high dose, hit hard and leave” approach) by their much smaller size, bi- and multi-specific targeting and tuneable half-life.
Crescendo is also using bespoke designs to create novel multi-specific IO modulators capable of targeting multiple mechanisms such as checkpoint inhibition, activating stimulatory pathways, enhancing antigen presentation and inhibiting the immunosuppressive tumour microenvironment

10/10/2016

Preclinical data presented at the European Society for Medical Oncology (ESMO) conference shows synergy of NOXXON’s lead compound NOX-A12 with both T cell and NK cell based therapies

Berlin, Germany – 10 October 2016 – NOXXON Pharma N.V. (Alternext Paris: ALNOX) a clinical-stage biopharmaceutical company primarily focused on cancer treatment, announced that it presented data yesterday at the ESMO conference in Copenhagen, Denmark, studying the role of CXCL12 inhibition by NOX-A12 (olaptesed pegol) in tumor stroma spheroids, a preclinical model that mimics the complexity of the tumor microenvironment. These studies showed that NOX-A12 synergizes with therapies working through either T cells or NK cells. Further studies of NOX-A12 with agents working through T cells such as checkpoint inhibitors or CAR-T cells as well as NK cell-based therapies are warranted.

Poster Title: CXCL12 Inhibition with NOX-A12 (Olaptesed Pegol) Increases T and NK Cell Infiltration and Synergizes with Immune Checkpoint Blockade and ADCC in Tumour-Stroma Spheroids
Authors: Dirk Zboralski, Anna Kruschinski, Dirk Eulberg and Axel Vater
Location & time: ESMO Congress 2016, Copenhagen, Denmark, 7-11 October 2016, Session Immunotherapy of cancer: Abstract #1083P, Hall E, Sunday, 9 October 2016, 13:00 – 14:00

The poster may be downloaded from the company’s website:
www.noxxon.com/downloads/poster/ESMO2016.pdf

NOX-A12, which inhibits the key tumor microenvironment chemokine CXCL12, may be a key partner for a wide range of IO (immuno-oncology) agents. NOXXON has generated promising pre-clinical and clinical data, including recent animal data showing synergy with a checkpoint inhibitor as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The company believes that additional clinical trials are warranted to investigate combinations of NOX-A12 multiple classes of IO agents including those acting on or through T cells and NK cells.

For more information, please contact:

NOXXON Pharma N.V.
Aram Mangasarian, Ph.D., Chief Executive Officer
Tel. +49 (0) 30 726 2470
amangasarian@noxxon.com

NewCap
Florent Alba
Tel. +33 (0) 1 44 71 98 55
falba@newcap.fr

About NOXXON
NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com

06/10/2016

Lausanne, Switzerland, October 6th, 2016 – Asceneuron SA, an emerging leader in the development of innovative small molecules for neurodegenerative diseases, today announced it has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) for the further development of positive allosteric modulators of the M1 muscarinic acetylcholine receptor (M1 PAMs). M1 PAMs induce a change in the shape of the receptor, enhancing binding to the neurotransmitter acetylcholine. As a result, receptor activity is potentiated so that it can fulfil its signaling functions, critical for cognition, even in situations where acetylcholine levels are reduced, as observed in dementia.

The grant from the MJFF Therapeutic Pipeline Program will support studies for the optimization of molecules to provide preclinical proof of concept in a relevant laboratory model. Asceneuron has already identified suitable lead molecules and will use its expertise in the field of muscarinic acetylcholine receptors and CNS drug development to achieve this objective. As this important receptor is critically involved in learning and memory, M1 PAMs have the potential as novel and efficacious medications to treat cognitive deficits in Parkinson’s disease dementia patients.

Commenting on the award, Dirk Beher (PhD), chief executive officer and co-founder of Asceneuron, said: “We are very excited to advance this approach to treating an underserved need. We expect our understanding of the novel biological interactions between M1 PAMs and the M1 muscarinic acetylcholine receptor to yield a Parkinson’s dementia therapy with potentially greater selectivity, fewer side effects and longer durability of effect.”
Marco Baptista (PhD), director of research programs at MJFF, added: “M1 PAMs could provide a new treatment option for Parkinson’s dementia, a critical current unmet need. We believe Asceneuron is making promising progress toward this goal.”

For further information, please contact:
Asceneuron
Dirk Beher, CEO
Email: info@asceneuron.com
Hume Brophy
Mary Clark, Eva Haas
Tel: +44 (0)20 7862 6395
Email: asceneuron@humebrophy.com

About Parkinson’s Disease and Parkinson’s Disease Dementia (PDD)
Parkinson’s disease is a progressive, degenerative neurological movement disorder that affects approximately 6.3 million people worldwide. Although it typically develops after the age of 65, about 15% of people with the condition develop « young-onset » Parkinson’s disease before reaching age 50.
As Parkinson’s disease progresses, it becomes increasingly disabling, making daily activities like bathing or dressing difficult or impossible. Many of the symptoms of Parkinson’s disease involve motor control, the ability to control your muscles and movement. Patients may also have problems with depression, sleep disruption and dementia. The cumulative prevalence of dementia can be as high as 78%, or 4.9 million sufferers globally, though it is most common in older patients. Neurochemically the most significant deficit in PDD is cholinergic which suggests that approaches focused on acetylcholine transmission and modulation may be effective treatment options.

About M1 PAMs
Positive allosteric modulators of the M1 muscarinic acetylcholine receptor (M1 PAMs) sensitize the receptor for its natural neurotransmitter acetylcholine. As a result, the M1 muscarinic receptor can still function in a situation where the release of acetylcholine is declining, as is observed in Parkinson’s and Alzheimer’s disease dementia. Since this receptor is critically involved in learning and memory, M1 PAMs have the potential to deliver novel and efficacious medications to treat cognitive deficits in Parkinson’s disease dementia patients as well as other dementia types including Dementia with Lewy Bodies (DLB) and Alzheimer’s disease.

About Asceneuron
Asceneuron is an emerging biotech company excelling in the development of orally bioavailable therapeutics for serious neurodegenerative disorders with high unmet medical needs such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, is currently completing the critical regulatory studies to initiate human clinical testing. The O-GlcNAcase inhibitor is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron is a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. For more information, please visit www.asceneuron.com.

About The Michael J. Fox Foundation
As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $600 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its
online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.